NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Myers E, Sanders GD, Ravi D, et al. Evaluating the Potential Use of Modeling and Value-of-Information Analysis for Future Research Prioritization Within the Evidence-Based Practice Center Program [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Jun. (Methods Future Research Needs Reports, No. 5.)

Cover of Evaluating the Potential Use of Modeling and Value-of-Information Analysis for Future Research Prioritization Within the Evidence-Based Practice Center Program

Evaluating the Potential Use of Modeling and Value-of-Information Analysis for Future Research Prioritization Within the Evidence-Based Practice Center Program [Internet].

Show details

References

1.
Outcome DEcIDE Center. Research on the Comparative Management of Uterine Fibroid Disease: A Report on the Priority-Setting Process, Preliminary Data Analyses, and Research Plan. Rockville, MD: Agency for Healthcare Research and Quality; Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc dba Outcome] under Contract No HHSA29020050035I TO5. [In press]
2.
Kunz K, Sainfort F, Butler M, et al. Decision and Simulation Modeling in Systematic Reviews [draft]. Rockville, MD: Agency for Healthcare Research and Quality; 2010. Prepared by the Minnesota Evidence-based Practice Center under Contract HHSA 290 2007 10064-I.
3.
Bouma JA, van der Woerd HJ, Kuik OJ. Assessing the value of information for water quality management in the North Sea. J Environ Manage. 2009;90(2):1280–1288. [PubMed: 18804324]
4.
Back PE, Rosen L, Norberg T. Value of information analysis in remedial investigations. Ambio. 2007;36(6):486–493. [PubMed: 17985703]
5.
Felli JC, Hazen GB. A Bayesian approach to sensitivity analysis. Health Econ. 1999;8(3):263–268. [PubMed: 10348421]
6.
Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 1998;18(1):95–109. [PubMed: 9456214]
7.
Claxton K, Ginnelly L, Sculpher M, et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol Assess. 2004;8(31):1–103. iii. [PubMed: 15248937]
8.
Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24(11):1055–1068. [PubMed: 17067191]
9.
Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006.
10.
Groot Koerkamp B, Weinstein MC, Stijnen T, et al. Uncertainty and patient heterogeneity in medical decision models. Med Decis Making. 2010;30(2):194–205. [PubMed: 20190188]
11.
Coleman CI, Baker WL, Kluger J, et al. Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; Oct, 2009. [Accessed September 7, 2010]. AHRQ Publication No. 10-EHC002. Available at: http://www​.effectivehealthcare​.ahrq.gov/reports/final.cfm. [PubMed: 20704041]
12.
Matchar DB, Myers ER, Barber MW, et al. Management of uterine fibroids. Evid Rep Technol Assess (Summ) 2001;(34):1–6. [PMC free article: PMC4781189] [PubMed: 11236283]
13.
Mooney C, Mushlin AI, Phelps CE. Targeting assessments of magnetic resonance imaging in suspected multiple sclerosis. Med Decis Making. 1990;10(2):77–94. [PubMed: 2112217]
14.
Walton SM, Schumock GT, Lee KV, et al. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008;28(12):1443–1452. [PMC free article: PMC4406412] [PubMed: 19025425]
15.
Kreiger N, Sloan M, Lacroix J. Establishing research priorities in etiologic epidemiology. Ann Epidemiol. 1999;9(1):19–24. [PubMed: 9915605]
16.
Temel T. A method for cross-sector priority setting. Gaps and hypotheses in malaria research: Tanzania. Eur J Health Econ. 2004;5(4):317–323. [PubMed: 15452735]
17.
Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Econ. 2009;18(2):203–216. [PubMed: 18435429]
18.
Koerkamp BG, Spronk S, Stijnen T, et al. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication. Value Health. 2009;13(2):242–250. [PubMed: 19818058]
19.
Willan AR, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. Health Econ. 2010;19(5):549–561. [PubMed: 19399753]
20.
Hornberger J. A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example. Am J Public Health. 1998;88(1):61–7. [PMC free article: PMC1508371] [PubMed: 9584035]
21.
Hornberger J, Eghtesady P. The cost-benefit of a randomized trial to a health care organization. Control Clin Trials. 1998;19(2):198–211. [PubMed: 9551284]
22.
Townsend J, Buxton M, Harper G. Prioritisation of health technology assessment. The PATHS model: methods and case studies. Health Technol Assess. 2003;7(20):iii, 1–82. [PubMed: 13678549]
23.
Noorani HZ, Husereau DR, Boudreau R, et al. Priority setting for health technology assessments: a systematic review of current practical approaches. Int J Technol Assess Health Care. 2007;23(3):310–315. [PubMed: 17579932]
24.
Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–181. [PubMed: 19075105]
25.
Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332(2):80–85. [PubMed: 7990904]
26.
Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670–1676. [PubMed: 7477219]
27.
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450–1456. [PubMed: 7654275]
28.
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–1587. [PubMed: 10821361]
29.
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–1675. [PubMed: 11759645]
30.
Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–766. [PubMed: 13678868]
31.
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–771. [PubMed: 13678869]
32.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906. [PubMed: 14610160]
33.
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. [PubMed: 18378520]
34.
Sanders GD, Powers B, Crowley M, et al. Future Research Needs for Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin II Receptor Blockers (ARBs) added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [draft], Prepared by the Duke Evidence-based Practice Center under Contract No. Contract No. HHSA 290-2007-10066-I. Rockville, MD: Agency for Healthcare Policy and Research; Nov, 2010. AHRQ Publication No. 10-EHC006-EF.
35.
Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151(12):861–871. [PubMed: 20008762]
36.
Sarafidis PA, Stafylas PC, Kanaki AI, et al. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21(8):922929. [PubMed: 18535536]
37.
Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–1562. [PubMed: 16980380]
38.
McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–1490. [PubMed: 20228403]
39.
Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51(6):1624–1630. [PubMed: 18413488]
40.
Nease RF Jr, Kneeland T, O’Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA. 1995;273(15):1185–1190. [PubMed: 7707625]
41.
Mathias SD, Bates MM, Pasta DJ, et al. Use of the Health Utilities Index with stroke patients and their caregivers. Stroke. 1997;28(10):1888–1894. [PubMed: 9341690]
42.
Brown GC, Brown MM, Sharma S, et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14(1):18–24. [PubMed: 10925062]
43.
Nordmann AJ, Krahn M, Logan AG, et al. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy. Pharmacoeconomics. 2003;21(8):573–585. [PubMed: 12751915]
44.
Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13(2):161–165. [PubMed: 8483401]
45.
Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80–87. [PubMed: 19911442]
46.
Day Baird D, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–107. [PubMed: 12548202]
47.
Myers ER, Barber MD, Gustilo-Ashby T, et al. Management of uterine leiomyomata: what do we really know? Obstet Gynecol. 2002;100(1):8–17. [PubMed: 12100798]
48.
Viswanathan M, Hartmann K, McKoy N, et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007;(154):1–122. [PMC free article: PMC4781116] [PubMed: 18288885]
49.
Carls GS, Lee DW, Ozminkowski RJ, et al. What are the total costs of surgical treatment for uterine fibroids? J Womens Health (Larchmt) 2008;17(7):1119–1132. [PubMed: 18687032]
50.
Lee DW, Ozminkowski RJ, Carls GS, et al. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. J Occup Environ Med. 2007;49(5):493–506. [PubMed: 17495692]
51.
Haas S, Acker D, Donahue C, et al. Variation in hysterectomy rates across small geographic areas of Massachusetts. Am J Obstet Gynecol. 1993;169(1):150–154. [PubMed: 8333443]
52.
Hassan C, Hunink MG, Laghi A, et al. Value-of-information analysis to guide future research in colorectal cancer screening. Radiology. 2009;253(3):745–752. [PubMed: 19789242]
53.
Hassan C, Pickhardt PJ, Di Giulio E, et al. Value-of-information analysis to guide future research in the management of the colorectal malignant polyp. Dis Colon Rectum. 2010;53(2):135–142. [PubMed: 20087087]
54.
Smits M, Dippel DW, Nederkoorn PJ, et al. Minor head injury: CT-based strategies for management--a cost-effectiveness analysis. Radiology. 2010;254(2):532–540. [PubMed: 20093524]
55.
Myers ER, Goodwin S, Landow W, et al. Prospective data collection of a new procedure by a specialty society: the FIBROID registry. Obstet Gynecol. 2005;106(1):44–51. [PubMed: 15994616]
56.
Ades AE, Mavranezouli I, Dias S, et al. Network meta-analysis with competing risk outcomes. Value Health. 2010;13(8):976–983. [PubMed: 20825617]
57.
Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313–2324. [PubMed: 12210616]
58.
Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate time horizons for research decisions? Medical Decision Making. 2008;28(3):287–299. [PubMed: 18448701]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.0M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...